MetaCap

BioStem Technologies (BSEM) vs Dyadic International (DYAI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dyadic International (DYAI) has outperformed BioStem Technologies (BSEM) over the past year, losing 68.8% versus a loss of 84.0%. Over five years, BSEM leads with a -55.9% price change compared with -92.2% for DYAI. BioStem Technologies is the larger company by market cap ($12.2 million vs $11.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BSEM-83.98%DYAI-68.80%
+116%+11%-94%
Nov 21, 20251 yearNov 20, 2026
BSEM-25.28%DYAI-92.56%
+2716%+1245%-226%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BSEM versus DYAI key metrics
MetricBSEMDYAI
Share price$0.6351$0.287
Market cap$12.18M$11.51M
1-day change-10.23%-7.66%
YTD return-83.33%-69.47%
1-year return-83.98%-68.80%
5-year return-55.90%-92.24%
P/E ratio (TTM)0.72—
Forward P/E2.19—
EPS (TTM)$0.88$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.09M
Revenue growth (YoY)—-11.59%
Net income (latest FY)—$-7.36M
Gross margin—24.93%
Operating margin—-232.75%
Net margin—-238.31%
52-week high$8.40$1.60
52-week low$0.5347$0.285
Distance from 52-week high-92.44%-82.06%
Analyst consensusnonenone
Avg. price target upside+1002.19%+1816.38%
Average volume194.93K140.81K
Shares outstanding19.18M40.09M
Employees735
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DYAI has outperformed BSEM by 15.2 percentage points over the past year.

About BioStem Technologies

BSEM stock →

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees

About Dyadic International

DYAI stock →

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

BSEM vs DYAI FAQ

Which is bigger, BioStem Technologies or Dyadic International?

BioStem Technologies (BSEM) is larger, with a market capitalization of $12.18M compared with $11.51M for Dyadic International (DYAI).

Which stock has performed better over the past year, BSEM or DYAI?

DYAI returned -68.80% over the past 12 months, compared with -83.98% for BSEM (price return, excluding dividends). Past performance does not predict future results.

Are BioStem Technologies and Dyadic International in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons